Lung Cancer Treatment Triplet Tested in Phase II Trial
A new three-drug combination was evaluated for patients with advanced EGFR-mutant lung cancer that progressed after prior treatment.
Updated on Oct. 6, 2026 in Cancer
A phase II clinical trial results released in May 2024 tested the safety and efficacy of combining amivantamab, lazertinib, and bevacizumab in 61 patients with EGFR-mutant advanced non-small cell lung cancer. This triplet therapy aims to provide a new option for patients whose disease has progressed on third-generation EGFR tyrosine kinase inhibitors.
Why it matters
As EGFR-mutant cancers frequently develop resistance to standard therapies, identifying effective next-line combinations is critical for managing disease progression. This study explored whether hitting multiple biological pathways simultaneously could offer better outcomes for patients with limited treatment options.
This phase II single-arm trial enrolled 61 patients to measure the impact of combining amivantamab, lazertinib, and bevacizumab. Findings included a 33% objective response rate at 12 weeks and a median progression-free survival of 10.9 months, though these are preliminary findings.
The players
Amivantamab
A bispecific antibody therapy targeting EGFR and MET mutations often used in advanced lung cancer treatment.
Lazertinib
A third-generation tyrosine kinase inhibitor designed to block EGFR mutations in non-small cell lung cancer.
Bevacizumab
An angiogenesis inhibitor that blocks the formation of new blood vessels required for tumor growth and survival.
The details
The treatment combines three agents to simultaneously target the EGFR and MET signaling pathways, as well as tumor angiogenesis. By attacking the cancer cells while also inhibiting the growth of new blood vessels that feed the tumor, the researchers sought to overcome resistance mechanisms developed after earlier targeted therapies. However, the regimen carried significant safety risks, with 43% of participants experiencing grade 3-4 adverse events.
Timeline
Trial enrollment began in March 2023.
Trial enrollment ended in May 2024.
Health Landscape
This study tracks the evolution of oncology in the context of the ongoing development of third-generation EGFR tyrosine kinase inhibitors, which currently serve as the standard of care for these mutations. The research explores whether triplet therapy can address the limitations of monotherapy as resistance inevitably develops.
Patients with EGFR-mutant lung cancer should discuss their current treatment trajectory and resistance patterns with their oncology care team. These results are specific to a clinical trial setting and highlight the importance of monitoring for potential side effects, such as venous thromboembolism.
The takeaway
Triplet therapy combinations are being explored to bypass resistance mechanisms in advanced lung cancer. Patients should keep a close watch on future phase III trial results and discuss clinical trial eligibility with their physician if standard-of-care options are no longer effective.
Further reading
Find more updates and research findings on treatment approaches in our Cancer section.
Source note: This article includes information reported by MedPage Today.
